References
- Vogelzang NJ, Breitbart W Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripartite assessment survey. Semin Hematol. 1997;34:4–12
- Mercadente S. Pharmacotherapy of anemia in cancer patients. Exp Opin Pharmacother 2001;2:1949–61.
- Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74
- Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumours. Ann Oncol 1993;4:161–7.
- Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84:1058–63.
- Abels RI, Larholt KM, Krantz KD, et al. recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. The Oncologist 1996;1:140–50.
- Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–9
- Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEPO) in anemia of malignancy. Haematologica 1996;81:434–41